내분비 약물 시장 보고서(2026년)

Endocrine drugs are pharmaceutical agents tailored to treat and control disorders of the endocrine system, encompassing glands like the thyroid, pancreas, and adrenals. They address conditions such as diabetes, thyroid issues, growth hormone shortages, and hormone imbalances, working to normalize hormone levels and enhance endocrine system performance.

Endocrinology drugs are primarily indicated for conditions like hyperthyroidism, hypothyroidism, diabetes, polycystic ovarian syndrome, growth hormone disorders, pituitary gland disorders, and more. Hyperthyroidism involves overproduction of thyroid hormones, resulting in symptoms including weight loss, fast heart rate, and nervousness. Key therapy categories encompass diabetes medications, drugs for thyroid hormone imbalances, human growth hormone, testosterone replacement therapy, and additional areas. These drugs reach patients via channels like hospital pharmacies, online pharmacies, and retail pharmacies, serving end users such as hospitals, ambulatory surgical centers, and others.

Tariffs have impacted endocrinology drugs by increasing the cost of imported APIs and hormone formulations used in chronic disease management. These effects are most visible in diabetes and thyroid therapy segments, where demand volumes and supply reliability are critical. Regions such as North America and Asia Pacific have experienced higher input costs due to reliance on cross border pharmaceutical sourcing. Rising tariff related expenses have influenced pricing strategies, reimbursement discussions, and procurement planning across endocrinology treatments. At the same time, tariffs have encouraged local production, expanded domestic manufacturing capacity, and strengthened regional pharmaceutical supply chains over the long term.

The endocrinology drugs market research report is one of a series of new reports from The Business Research Company that provides endocrinology drugs market statistics, including endocrinology drugs industry global market size, regional shares, competitors with a endocrinology drugs market share, detailed endocrinology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the endocrinology drugs industry. This endocrinology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The endocrinology drugs market size has grown marginally in recent years. It will grow from $26.2 billion in 2025 to $26.24 billion in 2026 at a compound annual growth rate (CAGR) of 0.1%. The growth in the historic period can be attributed to rising diabetes prevalence, increased thyroid disorder diagnosis, growth in hormone replacement usage, expansion of hospital pharmacies, improved endocrine awareness.

The endocrinology drugs market size is expected to see marginal growth in the next few years. It will grow to $26.42 billion in 2030 at a compound annual growth rate (CAGR) of 0.2%. The growth in the forecast period can be attributed to aging population, rising lifestyle-related disorders, growth in diabetes drug innovation, expansion of online pharmacies, increasing endocrine screening rates. Major trends in the forecast period include rising long-term management of chronic endocrine disorders, increasing use of combination hormonal therapies, growing demand for diabetes and thyroid disorder drugs, expansion of outpatient endocrine care, increased focus on hormone replacement therapies.

The increasing prevalence of endocrine diseases is anticipated to drive expansion in the endocrinology drugs market. Endocrine diseases involve disruptions to the endocrine system that lead to hormone production or regulation imbalances, disrupting normal bodily processes. This rise stems from factors like shifting lifestyles, a growing elderly population, and better diagnostic tools, all boosting the detection and occurrence of these disorders. Endocrinology drugs treat these conditions by normalizing hormone levels, correcting glandular issues, and reestablishing hormonal equilibrium to ease symptoms and enhance health results. For instance, in February 2025, the World Health Organization-a Switzerland-based UN agency dedicated to global public health-reported that polycystic ovary syndrome (PCOS) impacts 6 to 13% of women of reproductive age, with up to 70% of cases undiagnosed globally. Thus, the growing incidence of endocrine diseases is fueling demand in the endocrinology drugs market.

Major companies operating in the endocrinology drugs market are prioritizing product innovation and formulations like authorized generics of GLP-1 receptor agonists to boost patient access, cut treatment costs, and heighten competitiveness while upholding safety and efficacy. These tactics expand availability of essential diabetes and obesity therapies, fostering adherence to ongoing regimens-for instance, in June 2024, U.S.-based Teva Pharmaceuticals launched an authorized generic of Victoza (liraglutide) injection 1.8 mg in the United States, mirroring the branded product's formulation and benefits to offer clinicians and patients a budget-friendly option for managing type 2 diabetes and obesity, reflecting wider trends in generics that address surging global demand for such solutions.

In July 2024, AstraZeneca, a UK-based pharmaceutical company, acquired Amolyt Pharma Inc. for an undisclosed sum. Through this acquisition, AstraZeneca seeks to bolster its portfolio in rare endocrine diseases by incorporating Amolyt Pharma's promising pipeline of late-stage therapies. Amolyt Pharma Inc. is a France-based pharmaceutical company focused on developing treatments for rare endocrine diseases.

Major companies operating in the endocrinology drugs market are Johnson & Johnson Inc., Merck & Co. Inc., AbbVie Inc., Bayer Aktiengesellschaft, Novartis International AG, Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Biocon Limited, Boehringer Ingelheim International GmbH, Mylan N.V., Sandoz International GmbH, Ipsen Pharma, Ferring Pharmaceuticals Inc., Endocrine Pharma Private Limited

North America was the largest region in the endocrinology drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the endocrinology drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the endocrinology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The endocrinology drugs market consists of sales of insulin analogs, antithyroid drugs, and anti-diabetic drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Endocrinology Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses endocrinology drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for endocrinology drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The endocrinology drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Indication: Hyperthyroidism; Hypothyroidism; Diabetes; Polycystic Ovarian Syndrome; Growth Hormone Disorders; Pituitary Gland Disorders; Other Indications
• 2) By Therapy Area: Diabetes Drugs; Thyroid Hormone Disorder Drugs; Human Growth Hormone; Testosterone Replacement Therapy; Other Therapy Areas
• 3) By Distribution Channel: Hospital pharmacies; Online Pharmacies; Retail pharmacies
• 4) By End User: Hospitals; Ambulatory Surgical Centers; Other End Users
• Subsegments:
• 1) By Hyperthyroidism: Antithyroid Medications; Radioactive Iodine Therapy; Beta Blockers
• 2) By Hypothyroidism: Levothyroxine-based Medications; Liothyronine-based Medications; Combination Hormonal Therapies
• 3) By Diabetes: Insulin Therapies; Oral Antidiabetic Drugs (OADs); GLP-1 Receptor Agonists; SGLT-2 Inhibitors; DPP-4 Inhibitors
• 4) By Polycystic Ovarian Syndrome (PCOS): Oral Contraceptives; Metformin; Clomiphene Citrate; Anti-Androgens
• 5) By Growth Hormone Disorders: Recombinant Human Growth Hormone (rhGH); Growth Hormone Secretagogues; Growth Hormone Receptor Antagonists
• 6) By Pituitary Gland Disorders: Somatostatin Analogs; Gonadotropins; Dopamine Agonists
• 7) By Other Indications: Adrenal Gland Disorders; Osteoporosis; Parathyroid Disorders; Male Hormonal Imbalances
• Companies Mentioned: Johnson & Johnson Inc.; Merck & Co. Inc.; AbbVie Inc.; Bayer Aktiengesellschaft; Novartis International AG; Sanofi S.A.; AstraZeneca plc; Abbott Laboratories; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Amgen Inc.; Novo Nordisk A/S; Biocon Limited; Boehringer Ingelheim International GmbH; Mylan N.V.; Sandoz International GmbH; Ipsen Pharma; Ferring Pharmaceuticals Inc.; Endocrine Pharma Private Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Endocrinology Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Endocrinology Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Endocrinology Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Endocrinology Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Artificial Intelligence & Autonomous Intelligence
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Rising Long-Term Management Of Chronic Endocrine Disorders
  • 4.2.2 Increasing Use Of Combination Hormonal Therapies
  • 4.2.3 Growing Demand For Diabetes And Thyroid Disorder Drugs
  • 4.2.4 Expansion Of Outpatient Endocrine Care
  • 4.2.5 Increased Focus On Hormone Replacement Therapies

5. Endocrinology Drugs Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Ambulatory Surgical Centers
• 5.3 Specialty Endocrine Clinics
• 5.4 Retail Pharmacies
• 5.5 Online Pharmacies

6. Endocrinology Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Endocrinology Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Endocrinology Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Endocrinology Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Endocrinology Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Endocrinology Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Endocrinology Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Endocrinology Drugs Market Segmentation

• 9.1. Global Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hyperthyroidism, Hypothyroidism, Diabetes, Polycystic Ovarian Syndrome, Growth Hormone Disorders, Pituitary Gland Disorders, Other Indications
• 9.2. Global Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Diabetes Drugs, Thyroid Hormone Disorder Drugs, Human Growth Hormone, Testosterone Replacement Therapy, Other Therapy Areas
• 9.3. Global Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital pharmacies, Online Pharmacies, Retail pharmacies
• 9.4. Global Endocrinology Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Ambulatory Surgical Centers, Others End Users
• 9.5. Global Endocrinology Drugs Market, Sub-Segmentation Of Hyperthyroidism, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Antithyroid Medications, Radioactive Iodine Therapy, Beta Blockers
• 9.6. Global Endocrinology Drugs Market, Sub-Segmentation Of Hypothyroidism, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Levothyroxine-based Medications, Liothyronine-based Medications, Combination Hormonal Therapies
• 9.7. Global Endocrinology Drugs Market, Sub-Segmentation Of Diabetes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Insulin Therapies, Oral Antidiabetic Drugs (OADs), GLP-1 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors
• 9.8. Global Endocrinology Drugs Market, Sub-Segmentation Of Polycystic Ovarian Syndrome (PCOS), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral Contraceptives, Metformin, Clomiphene Citrate, Anti-Androgens
• 9.9. Global Endocrinology Drugs Market, Sub-Segmentation Of Growth Hormone Disorders, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Recombinant Human Growth Hormone (rhGH), Growth Hormone Secretagogues, Growth Hormone Receptor Antagonists
• 9.10. Global Endocrinology Drugs Market, Sub-Segmentation Of Pituitary Gland Disorders, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Somatostatin Analogs, Gonadotropins, Dopamine Agonists
• 9.11. Global Endocrinology Drugs Market, Sub-Segmentation Of Other Indications, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Adrenal Gland Disorders, Osteoporosis, Parathyroid Disorders, Male Hormonal Imbalances

10. Endocrinology Drugs Market Regional And Country Analysis

• 10.1. Global Endocrinology Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Endocrinology Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Endocrinology Drugs Market

• 11.1. Asia-Pacific Endocrinology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Endocrinology Drugs Market, Segmentation By Indication, Segmentation By Therapy Area, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Endocrinology Drugs Market

• 12.1. China Endocrinology Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Endocrinology Drugs Market, Segmentation By Indication, Segmentation By Therapy Area, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Endocrinology Drugs Market

• 13.1. India Endocrinology Drugs Market, Segmentation By Indication, Segmentation By Therapy Area, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Endocrinology Drugs Market

• 14.1. Japan Endocrinology Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Endocrinology Drugs Market, Segmentation By Indication, Segmentation By Therapy Area, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Endocrinology Drugs Market

• 15.1. Australia Endocrinology Drugs Market, Segmentation By Indication, Segmentation By Therapy Area, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Endocrinology Drugs Market

• 16.1. Indonesia Endocrinology Drugs Market, Segmentation By Indication, Segmentation By Therapy Area, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Endocrinology Drugs Market

• 17.1. South Korea Endocrinology Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Endocrinology Drugs Market, Segmentation By Indication, Segmentation By Therapy Area, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Endocrinology Drugs Market

• 18.1. Taiwan Endocrinology Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Endocrinology Drugs Market, Segmentation By Indication, Segmentation By Therapy Area, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Endocrinology Drugs Market

• 19.1. South East Asia Endocrinology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Endocrinology Drugs Market, Segmentation By Indication, Segmentation By Therapy Area, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Endocrinology Drugs Market

• 20.1. Western Europe Endocrinology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Endocrinology Drugs Market, Segmentation By Indication, Segmentation By Therapy Area, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Endocrinology Drugs Market

• 21.1. UK Endocrinology Drugs Market, Segmentation By Indication, Segmentation By Therapy Area, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Endocrinology Drugs Market

• 22.1. Germany Endocrinology Drugs Market, Segmentation By Indication, Segmentation By Therapy Area, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Endocrinology Drugs Market

• 23.1. France Endocrinology Drugs Market, Segmentation By Indication, Segmentation By Therapy Area, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Endocrinology Drugs Market

• 24.1. Italy Endocrinology Drugs Market, Segmentation By Indication, Segmentation By Therapy Area, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Endocrinology Drugs Market

• 25.1. Spain Endocrinology Drugs Market, Segmentation By Indication, Segmentation By Therapy Area, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Endocrinology Drugs Market

• 26.1. Eastern Europe Endocrinology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Endocrinology Drugs Market, Segmentation By Indication, Segmentation By Therapy Area, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Endocrinology Drugs Market

• 27.1. Russia Endocrinology Drugs Market, Segmentation By Indication, Segmentation By Therapy Area, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Endocrinology Drugs Market

• 28.1. North America Endocrinology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Endocrinology Drugs Market, Segmentation By Indication, Segmentation By Therapy Area, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Endocrinology Drugs Market

• 29.1. USA Endocrinology Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Endocrinology Drugs Market, Segmentation By Indication, Segmentation By Therapy Area, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Endocrinology Drugs Market

• 30.1. Canada Endocrinology Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Endocrinology Drugs Market, Segmentation By Indication, Segmentation By Therapy Area, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Endocrinology Drugs Market

• 31.1. South America Endocrinology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Endocrinology Drugs Market, Segmentation By Indication, Segmentation By Therapy Area, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Endocrinology Drugs Market

• 32.1. Brazil Endocrinology Drugs Market, Segmentation By Indication, Segmentation By Therapy Area, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Endocrinology Drugs Market

• 33.1. Middle East Endocrinology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Endocrinology Drugs Market, Segmentation By Indication, Segmentation By Therapy Area, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Endocrinology Drugs Market

• 34.1. Africa Endocrinology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Endocrinology Drugs Market, Segmentation By Indication, Segmentation By Therapy Area, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Endocrinology Drugs Market Regulatory and Investment Landscape

36. Endocrinology Drugs Market Competitive Landscape And Company Profiles

• 36.1. Endocrinology Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Endocrinology Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Endocrinology Drugs Market Company Profiles
  • 36.3.1. Johnson & Johnson Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis

37. Endocrinology Drugs Market Other Major And Innovative Companies

• Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Biocon Limited, Boehringer Ingelheim International GmbH, Mylan N.V., Sandoz International GmbH, Ipsen Pharma, Ferring Pharmaceuticals Inc., Endocrine Pharma Private Limited

38. Global Endocrinology Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Endocrinology Drugs Market

40. Endocrinology Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Endocrinology Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Endocrinology Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Endocrinology Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer